诊断至治疗间隔是新诊断弥漫性大B细胞淋巴瘤的重要临床因素,并对临床试验偏倚有提示意义
在美国基于临床的观察队列(MER,N=986)和欧洲基于临床试验的队列(LYSA,N=1444)中,新诊断DLBCL患者诊断至治疗间隔(中位MER 15天,LYSA 23天)与不良临床因素强烈相关,且较长间隔与24个月无事件生存率改善相关(MER每周OR 0.80,95%CI 0.74-0.87;LYSA每周OR 0.90,95%CI 0.86-0.94)。
要点
- 较短诊断至治疗间隔与不良临床因素(LDH升高、体能状态差、B症状、IPI较高)强烈相关。
- 较长诊断至治疗间隔与24个月无事件生存率改善相关,调整IPI后仍显著。
- 诊断至治疗间隔应在新诊断DLBCL临床试验中报告,未来试验应避免因治疗延迟导致的选择偏倚。
核心结论
- 诊断至治疗间隔与新诊断DLBCL的预后临床因素和结局强烈相关,应在所有新诊断DLBCL临床试验中报告,未来试验应避免因治疗延迟导致的选择偏倚。
研究设计与样本
- 美国基于临床的观察队列(University of Iowa和Mayo Clinic SPORE MER,N=986)和欧洲基于临床试验的队列(LYSA LNH-2003,N=1444),患者均接受蒽环类为基础的免疫化疗。
主要发现
- 中位诊断至治疗间隔(范围)在MER为15天(0至155天),在LYSA为23天(0至215天)。
- 较短诊断至治疗间隔在两个队列中均与不良临床因素强烈相关,包括乳酸脱氢酶升高、体能状态差、B症状和较高国际预后指数(均P<.001)。
- 较长诊断至治疗间隔与24个月无事件生存率改善相关,MER每周比值比0.80(95%CI 0.74至0.87),LYSA每周比值比0.90(95%CI 0.86至0.94)。
- 调整国际预后指数后,诊断至治疗间隔与24个月无事件生存率的关联仍显著。
关键数值与推荐
- 较长诊断至治疗间隔与24个月无事件生存率改善相关:MER每周比值比0.80(95%CI 0.74至0.87),LYSA每周比值比0.90(95%CI 0.86至0.94)。
- 较短诊断至治疗间隔与不良临床因素相关(均P<.001)。
临床怎么用
- 诊断至治疗间隔应在新诊断DLBCL临床试验中报告,未来试验应采取措施避免因治疗延迟导致的选择偏倚。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the consent process and the inability to delay therapy for eligibility evaluation. We have examined the diagnosis-to-treatment interval (DTI) and its association with clinical factors and outcome in a clinic-based observational cohort of patients with DLBCL from the United States. Validation of results was performed in an independent, clinical trial-based cohort from Europe. Patients and Methods Patients were prospectively enrolled in the University of Iowa and Mayo Clinic Specialized Programs of Research Excellence Molecular Epidemiology Resource (MER; N = 986) or the Lymphoma Study Association (LYSA) LNH-2003 clinical trials program (N = 1,444). All patients received anthracycline-based immunochemotherapy at initial diagnosis. Associations of DTI with clinical factors and outcome were examined. Outcome was assessed using event-free survival at 24 months from diagnosis (EFS24). Results Median (range) DTI was 15 days (0 to 155 days in the MER and 23 days (0 to 215 days) in LYSA. Shorter DTI was strongly associated with adverse clinical factors, including elevated lactate dehydrogenase levels, poor performance status, B symptoms, and higher International Prognostic Index in both cohorts (all P < .001). Longer DTI was associated with improved EFS24 in both the MER (per-week odds ratio, 0.80; 95% CI, 0.74 to .0.87) and LYSA (per-week odds ratio, 0.90; 95% CI, 0.86 to 0.94); association with EFS24 remained significant after adjustment for International Prognostic Index. Conclusion DTI is strongly associated with prognostic clinical factors and outcome in newly diagnosed DLBCL. DTI should be reported in all clinical trials of newly diagnosed DLBCL and future trials should take steps to avoid selection bias due to treatment delay.
引用
- Maurer MJ, Ghesquières H, Link BK, et al. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol. 2018. PMID: 29672223. doi:10.1200/JCO.2017.76.5198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。